Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
Onconova Therapeutics (NASDAQ: ONTX) is set to participate in the 2023 Guggenheim Oncology Conference in New York City on February 8-9, 2023. CEO Steven Fruchtman will host a fireside chat on February 8 at 10:45 a.m. ET, with a replay available on the company's website. The company will also engage in one-on-one investor meetings at the conference. Onconova is dedicated to advancing innovative anti-cancer therapies, with ongoing Phase 1 studies for its multi-kinase inhibitor narazaciclib and rigosertib evaluations in various cancers. For more details, visit www.onconova.com.
- None.
- None.
NEWTOWN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the 2023 Guggenheim Oncology Conference taking place February 8-9, 2023 in New York City.
Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 8, 2023, at 10:45 a.m. ET. A webcast of the fireside chat will be available here. Following the presentation, a replay will be archived on the “Corporate Events and Presentations” section of the Onconova website.
The Company will also be participating in 1x1 investor meetings at the conference on February 8 and 9, 2023. Meetings can be requested via Guggenheim.
About Onconova Therapeutics
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also planning a combination trial of narazaciclib with estrogen blockade in advanced endometrial cancer, as well as its clinical study in additional indications.
Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, and a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
For more information, please visit www.onconova.com.
Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
What is Onconova Therapeutics participating in on February 8-9, 2023?
Who is representing Onconova at the Guggenheim Conference?
What time is Onconova's fireside chat during the conference?
How can I access the replay of Onconova's fireside chat?
What are Onconova's key drug candidates?
